Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- Donald Trump Face Coins Spark Snarky Viral Reactions
- Does Burrata Go Bad? Everything You Should Know
- TikTok Diagnosed Me With ‘Ferritin Face’. WTF Does That Mean?
- Demystifying Grounding Queries with Real Data
- Pangram’s Max Spero on why AI detection is harder than ‘Real or Fake’
- Don’t Fall For This Alarming Jury Duty Scam
- INJ Price Prediction: Short Squeeze Brewing at $4.84 — $5.91 or Bust Before Week’s End – BitRss
- Mike Johnson Makes Bold Claim About Iranians And… Irony, Much?
Browsing: Investment
Some investors are increasing their exposure to bank stocks ahead of reports on a turmoil-filled first quarter. …
The firm is raising its outlook again on tech giant Apple, and expects a strong earnings report on iPhone dominance and a rebound in demand in…
Analysts and investors took to CNBC to discuss the latest action for Amazon shares. …
"Ask Halftime" traders answer your questions about individual stocks and ETFs. …
Investors have been treading lightly around ether this year, but with "Shanghai" uncertainty out of the way, ether may finally catch up with bitcoin. …
Follow Cerity Partners Chief Equity Strategist Jim Lebenthal as he previews big bank earnings and how he is positioning his money for what's to come. …
Bank of America screened for underowned stocks its analysts think could top Wall Street's first-quarter earnings estimates. …
Goldman Sachs is eyeing call options on two of the biggest players in the tech industry, as earnings week could bring a major lift to both…
Weight-loss drug Wegovy has had a successful relaunch, while diabetes drug Ozempic has seen accelerating growth, Credit Suisse said. …
Evercore ISI's analyst listed two of his favorite names in the sector, and one stock to bet against. …
Retail traders appear to be selectively buying the dip in some stocks hit hard by the regional bank crisis, according to JPMorgan. …
Here are the biggest calls on Wall Street on …
Citi thinks it's time to buy Steven Madden shares. …
Citi upgraded Merck shares to buy and raised its price target to $130. The firm believes that Merck's drug pipeline is underappreciated by the market. …